×
About 1,613 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  402 results

Altered leukocyte subsets and immune proteome indicate pro-inflammatory mechanisms in m...
https://doi.org/10.1016/j.jaci.2021.12.786
The Journal of Allergy and Clinical Immunology; Hermans MAW, Heeringa JJ et. al.

Jan 14th, 2022 - Indolent systemic mastocytosis (ISM) is characterized by pathological accumulation of mast cells. The mechanism behind its phenotypic heterogeneity is not well understood. Interaction of mast cells with other immune cells might cause systemic infl...

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

Jan 12th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

Dec 22nd, 2021 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04996875

Dec 16th, 2021 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...

see more →

Guidelines  1 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

see more →

Drugs  179 results see all →

Clinicaltrials.gov  16 results

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

Jan 12th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

Dec 22nd, 2021 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04996875

Dec 16th, 2021 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
https://clinicaltrials.gov/ct2/show/NCT04333108

Nov 30th, 2021 - Masitinib is a selective tyrosine kinase inhibitor that modulates mast cell activity via inhibition of c-Kit, Lyn and Fyn kinase signaling pathways. This is a multicenter, randomized, double-blind, placebo-controlled, 2-parallel-group, trial compa...

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03731260

Oct 26th, 2021 - This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not ade...

see more →

News  43 results

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

NICE Recommends First Treatment for Mastocytosis
https://www.medscape.com/viewarticle/957272

Aug 26th, 2021 - The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending midostaurin (Rydapt, Novartis) as a treatment for advanced systemic mastocytosis in adults. There are three diverse subtypes of the rare hae...

Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia
https://www.onclive.com/view/well-differentiated-systemic-mastocytosis-vs-chronic-mast-cell-leukemia

Aug 19th, 2021 - Dan DeAngelo, MD, PhD: That’s a phenomenal presentation of a very a rare disease. Now, we’re talking about hen’s teeth in a rare disease. I have seen a lot of mast cells, but I have only seen 2 cases of well-differentiated systemic mastocytosis [W...

Case 4: A 68-Year-Old Female With Mast Cell Leukemia
https://www.onclive.com/view/case-4-a-68-year-old-female-with-mast-cell-leukemia

Aug 19th, 2021 - Sa Wang, MD: I’ll show a couple of cases. I don’t have very detailed treatment information, but I think I have 3 cases. I’ll show some variety in a different diagnostic entity within this category of SM [systemic mastocytosis]. This is a 68-year-o...

Case 3: Indolent Systemic Mastocytosis
https://www.onclive.com/view/case-3-indolent-systemic-mastocytosis

Aug 19th, 2021 - Dan DeAngelo, MD, PhD: I think the next case will be right up your alley, Dr. Lugar, in terms of highlighting a case that was a challenge. This is a patient of mine who presented with urticaria pigmentosa, 15 years ago now, 2006; and more prominen...

see more →

Patient Education  4 results see all →